Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Invitrogen Corp.

May 2007
In California, Invitrogen Corp. of Carlsbad will partner with Emiliem Inc. of Emeryville to screen the latter’s cancer-targeting multiple kinase inhibitors. Under terms of the agreement, Invitrogen will use its SelectScreen kinase profiling system to confirm the potency and specificity of compounds created using Emiliem’s K-Star technology. In the second phase of investigations, the former company will analyze with its cellular profiling system how the compounds influence biological pathways. Through cytochrome P450 screening, the company will assess the inhibitory effects of the molecules on drug-metabolizing liver enzymes as well.

BiophotonicsInvitrogen Corp.News & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.